Close
Patheon

Patheon Newsroom

  • 29 Jun 2017
    Investments in key service areas to meet growing customer demand

    Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, today announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer...

  • 08 Jun 2017
    Highlights: 2Q 2017 revenue of $483 million Net income from continuing operations of $28 million Net income from continuing operations per diluted share of $0.19 2Q 2017 Adjusted EBITDA of $94 million Adjusted net income from continuing operations of $29 million Adjusted net income from continuing operations per diluted share of $0.20

    Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017.

  • 15 May 2017
    -- Patheon Provides Entry into the Attractive, High-growth CDMO Market -- Combination Significantly Strengthens Thermo Fisher's Unique Value Proposition for Pharmaceutical and Biotech Customers by Adding Highly Complementary Services -- Creates Substantial Synergies and Positions Combined Company to Further Accelerate Growth -- Expected to be Immediately and Significantly Accretive to Adjusted Earnings Per Share (EPS)

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo...

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

Patheon on Twitter

 
 

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

Patheon on Twitter